Hauschild, A., & Schadendorf, D. (2016). Prospective randomized trial of interferon Alfa-2b and Interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. Journal of clinical oncology, 21(15), . https://doi.org/10.1200/JCO.2003.07.116
Chicago-Zitierstil (17. Ausg.)Hauschild, Axel, und Dirk Schadendorf. "Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-risk Primary Melanoma Without Clinically Detectable Node Metastasis." Journal of Clinical Oncology 21, no. 15 (2016). https://doi.org/10.1200/JCO.2003.07.116.
MLA-Zitierstil (9. Ausg.)Hauschild, Axel, und Dirk Schadendorf. "Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-risk Primary Melanoma Without Clinically Detectable Node Metastasis." Journal of Clinical Oncology, vol. 21, no. 15, 2016, https://doi.org/10.1200/JCO.2003.07.116.